Skip to main content

Table 2 Concentration and frequency of β-thymosins in scleroderma patients and controls.

From: β-thymosins and interstitial lung disease: study of a scleroderma cohort with a one-year follow-up

  46 scleroderma pts 15 controls
presence of Tβ4, n pts (%) 46 (100%) 15 (100%)
4 (μmol/L, mean ± SD) 0.310 ± 0.372* 0.112 ± 0.084
(median, range) (0.21, 0-2.1) (0.09, 0-0.26)
presence of sTβ4, n pts (%) 14 (30%) 5 (33%)
sTβ4 (μmol/L, mean ± SD) 0.016 ± 0.041 0.007 ± 0.011
(median, range) (0,0-0.24) (0.01, 0-0.08)
presence of Tβ10, n pts (%) 28 (60.9%) 8 (53.3%)
10 (μmol/L, mean ± SD) 0.050 ± 0.072 0.017 ± 0.022
(median, range) (0.02, 0-0.3) (0, 0-0.04)
4/sTβ4 ratio (mean ± SD) 9.4 ± 2.6 11.0 ± 4.6
  1. 4: thymosin β4; n: number; pts: patients; SD: standard deviation; sTβ4: thymosin β4 sulfoxide; Tβ10: thymosin β10.
  2. *p < 0.05: pts versus controls